8:30 Registration & Coffee
9:10 CHAIRMAN'S OPENING PRESENTATION
Dimitri F Dimitriou, Senior Director, Worldwide Business Development, GlaxoSmithKline
Financing trends in the biotech sector Creating opportunities in life sciences Collaborations: the lifeblood of biotechs 9:40 REVIEWING THE TECHNICAL AND COMMERCIAL ASSESSMENT OF DEVELOPMENT STAGE TECHNOLOGIES
Adam Raman, Director, Strategy Development, PHASE II International
Strategic needs of emerging companies: from set up to launch Assessing scientific innovation vs generating financial forecasts: critique valuation methods Developing the need for a technology valuation scoring system Understanding the individual needs of various stakeholders Developing communication strategies targeted to the different needs of stakeholders 10:20 IS YOUR MOLECULE READY TO MARKET OR PARTNER?
Mark A King, Managing Director, Kendall Strategies
Historically, the pharma and biotech industries have focused on the NDA, not the market, when designing clinical programs This myopia often resulted in unnecessary marketing limitations due to an unnecessarily restrictive label This presentation will discuss new strategies for evaluating drug candidates and their markets in order to realise a molecule’s full potential either in the market or in a partnering deal One or more case studies will be presented 11:00 Morning Coffee
11:20 COMMERCIALISING A LEAD CANCER PRODUCT
Dr Elma S Hawkins, Vice Chairman, Antigenics
Developing an integrated infrastructure to develop and commercialise Oncophage® Expanding the clinical development programme Building a sales force prior to commercialisation Creating value through prudent funding strategies 12:00 TECHNOLOGY TRANSFER
Glynn Edwards, Chief Executive Officer, Antisoma
Why transfer technology from universities? Recognising the commercial implications of academic discoveries What are the stages of technology transfer and commercialisation? What are the options for technology commercialisation from academia? Established companies, start-ups or spin-offs? Bringing science and commercial groups together 12:40 Networking Lunch
14:00 COMMERCIALISING TECHNOLOGY FROM ACADEMIA
Prof Howard Stevens, Pfizer Professor of Exploratory Drug Delivery, Department of Pharmaceutical Sciences,, University of Strathclyde, UK
An industrialist links with academics An industrialist joins an academic spin-out From buy-out to acquisition to academic chair Start-up / spin-out of a service business Spin-out of a R&D business 14:40 FROM ACADEMIA TO BIOTECH: A SUCCESS STORY
Dr John Brown, Chief Executive Officer, Acambis
A brief history of Acambis From university to biotech: the stages of company development and technology
commercialisation
Technology platforms for new vaccines Commercialising the technology Strengthening the financial position through alliances Focusing the portfolio
Maintaining a strategy for constant new product opportunities
15:20 Afternoon Tea
15:40 TECHNOLOGY TRANSFER: THE HUMAN FACTOR
Cynthia Larbey, Managing Director, People in Health
Understanding the stages and some of the issues involved Working toward speeding up the process from innovation to commercialisation What human skills are required for successful technology transfer? Finding the right teams Integrating the scientific and commercial teams Planning for success, some good and bad examples 16:20 FROM THE LABORATORY TO THE MARKET-PLACE
Dr Peter MacLennan, Director of Business Development, Pharma-Transfer
Historical perspective: what motivates scientists? The current situation: how do scientists link up with business? Geographical comparisons: US vs European culture Venture capital, biotechnology companies, big Pharma – an exploration of their different roles The future: where will we be in five years time? 17:00 Chairman’s Closing Remarks and Close of Day One
17:10 Networking Drinks Reception
8:30 Re-registration and Coffee
9:00 Chairman's Opening Remarks
Dr Nigel Parker, Chief Executive Officer, Ark Therapeutics
9:40 RAISING FINANCIAL SUPPORT FOR COMMERCIALISATION
Stephanie Léouzon, Managing Director, Credit Suisse First Boston
The new issue market and raising funds through initial public offering (IPO) Advantages and disadvantages of ‘going public’ for the biotech start-up Pros and cons of private placements Venture capital financing Trends in venture capital financing in the US and Europe
Qualitative and quantitative analyses of venture capital funding trends
Advantages and disadvantages 10:20 COMMERCIALISING A DRUG-DISCOVERY PROCESS IN ANTI-INFECTIVE RESEARCH
Prof. Ken Powell, Chief Executive Officer, Arrow Therapeutics
World leading science Strong management Clear business model Broad product portfolio Supportive investors 11:00 Morning Coffee
11:20 RISK MANAGEMENT AND BARRIERS TO COMMERCIALISATION
Dr Stephen Castle, Managing Director, Mattson Jack Group-Europe
Does biotechnology involve such high-risks? Understanding barriers Understanding risks Strategies to overcome barriers and manage risks Developing a successful commercialisation strategy acknowledging risk and barriers 12:00 M&A AS A STRATEGY FOR COMMERCIALISATION
Geoff Collett, Vice President, Corporate Development, Lorus Therapeutics
Facing the harsh imperative of M&A Ambitious business models required for a new era Acquisition of critical mass Diversification of development risk Capabilities versus cash Maximising valuation and providing liquidity options to shareholders 12:40 Networking Lunch
14:00 THE IMPACT OF PHARMACOGENOMICS ON DRUG DISCOVERY, DEVELOPMENT AND COMMERCIALISATION
Dr Bruce L Maloff, Executive Vice President, Commercial Operations, Variagenics
Overcoming ‘pharmacogenomicsophobia’ Attuning drug development to genetic variability Targeting blockbusters and eliminating non-responders Making pharmacogenomics happen Changing the diagnostics paradigm Healthcare impact 14:40 IMPLEMENTING DECISION ANALYSIS IN THE PHARMACEUTICAL ARENA
Dr Steven Kuemmerle, Director, Decision Support Group, Abbott Laboratories
A brief history of decision analysis (DA) and its application to R&D intensive enterprises A review of the application of DA to problems in pharmaceutical development How to assess development risk, commercial return and produce high quality decisions Case study: How DA was implemented at Abbott How Abbott uses DA in pharma development 15:20 Afternoon Tea
15:40 TECHNOLOGY MANAGEMENT
David Best, Chairman, Medical Marketing International Group
Pharmaceutical market consolidation The needs of academia The MMI model Strategic alliances The investor’s view 16:20 STRATEGIES, NEED AND IMPACT OF HIGH QUALITY COMBINATORIAL CHEMISTRY ON DRUG DISCOVERY CAPABILITIES OF THE PHARMACEUTICAL
INDUSTRY IN THE POST-GENOMICS ERA
Dr Kumar G Gadamasetti, Senior Director, ChemRx Advanced Technologies [Discovery Partners International]
Augment the internal drug discovery capabilities of pharmaceutical and biopharmaceutical companies Broaden and deepen our technology through internal inventions, acquisitions, multiple revenue streams and expand our knowledge base Understand what business partners want A clear pathway from research ideas to high quality products Fully integrated chemistry platform Good combinatorial libraries come from good science 17:00 Chairman's Closing Remarks and Close of Conference
9:10 EARLY STAGE FUNDING
Antony Ross, Director, Healthcare, 3i Group